Company ProfilePremium

Medinex Limited

Company Profile Analysis

Ticker: OTX.SI

ESOMAR 23 Corporate BadgeISO Certifications Badge
Medinex Limited - Company showcase

Year Founded & Workforce

2009

65 Employees

Medinex Limited logo

Medinex Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Medinex Limited Overview

Medinex Limited is a Singapore-based, Catalist-listed holding company that provides outsourced professional support to private medical practices, and to a lesser extent to non-healthcare SMEs. Its core proposition is a one-stop platform for doctors who want to start, run and grow a clinic: setting up the clinic and handling licensing, accounting, tax, corporate secretarial, HR and payroll, and procuring pharmaceuticals and medical consumables. Its stated vision is to be the preferred multi-disciplinary support platform for its clients. Four reported segments generated S$12.4m of revenue in FY2026. The two high-margin service segments (Medical Support and Business Support) generate almost all segment profit. Pharmaceutical procurement is loss-making after impairment, and Medical Services was discontinued on 31 March 2026. The group is net-cash, pays a steady dividend of 1.68 Singapore cents per share, and faces pricing pressure, consolidation of private healthcare, tighter Integrated Shield Plan rules and AI-driven disruption of transactional bookkeeping.


Company's own description (Annual Report 2026)

Paraphrasing AR2026's corporate profile: Medinex describes itself as a Singapore-based medical support services provider specialising in professional support services to medical clinics. Its medical support scope covers overseeing clinic set-ups, helping obtain clinic licences, and business support such as accounting, tax agent services, HR management and corporate secretarial services. It also provides X-ray, pre-employment check-up and health screening services (the Medical Services segment, discontinued from 31 March 2026). Its pharmaceutical services help clients procure medical and pharmaceutical products from authorised distributors in Singapore. As an ancillary activity, it provides accounting, tax and corporate services to companies outside healthcare, with clients in food and beverage, retail, education and beauty. Medinex is an Accredited Training Organisation (ATO) for the Chartered Accountant (Singapore) designation. Its mission statement frames it as a trusted partner helping clients "start, sustain and succeed".

Independent characterisation

Economically, Medinex is a small professional-services roll-up with a healthcare vertical focus. Since its 2018 IPO it has grown mainly by buying small, founder-run accounting, corporate-secretarial and HR consultancies (Ark Leadership & Learning, the SKI group, AccTax, Carlin Management Services) and putting them on a shared back office, including a lower-cost team in Malaysia. Healthcare enters the model in three ways:

  1. Clinic-facing professional services. Clinic set-up projects, licensing support, and recurring compliance work for general practitioners (GPs) and specialists. This is the Medical Support Services segment.

  2. Pharmaceutical procurement. Through Nex Healthcare Pte. Ltd., Medinex buys medicines and consumables from authorised Singapore distributors and delivers them to clinics using two company vans. This is a low-margin trading activity, and in FY2026 it was exposed to customer concentration.

  3. Direct medical services. X-ray, health screening and pre-employment checks through Sen Med and later Express Medical. This line shrank from S$1.95m of revenue in FY2022 to S$0.49m in FY2026 and was discontinued when Express Medical was sold on 31 March 2026.

Revenue model

Revenue type (as disclosed)FY2024FY2025FY2026
Service fees (S$'000)8,7689,0259,132
Sale of medical and pharmaceutical products (S$'000)3,3083,2882,789
Provision of medical services (S$'000)509500493
Total revenue (S$'000)12,58512,81312,414
Timing of revenue recognitionFY2024FY2025FY2026
Point in time (S$'000)11,49311,55111,401
Over time (S$'000)1,0921,2621,013

Source: FY2025 and FY2026 results announcements, Note 4.2 (disaggregation of revenue).

Source: FY2025 and FY2026 results announcements, Note 4.2.

In FY2026 the mix was about 74% professional service fees, 22% product resale and 4% medical services. There is no licensing or software subscription revenue. Much of the service-fee revenue recurs in practice, because annual compliance engagements (statutory accounts, tax filings, AGM secretarial work, payroll) repeat each year, even though most is recognised at a point in time. The company does not disclose a recurring-revenue percentage or customer retention metrics.

Value-chain position and customers

Value-chain position: Medinex is a downstream service intermediary. It does not manufacture products or employ treating doctors at scale. In pharmaceuticals it is a procurement and distribution intermediary between authorised distributors and clinics; all FY2026 procurement spending was with local suppliers (AR2026).

Customer types: Private GPs and specialists in Singapore's primary and secondary care sectors; clinic owners setting up new practices; corporates buying health screening and pre-employment services (until March 2026); and SMEs outside healthcare (F&B, retail, education, beauty) buying accounting, tax and corporate secretarial services.

End-markets: Singapore private healthcare and Singapore SME corporate services. Malaysia is used mainly as a support and cost base (Medinex Corporate Services Sdn. Bhd.). Revenue by geography is not disclosed.

Strategy

Stated strategic themes (AR2026 Chairman and CEO message)

Paraphrasing AR2026, management's priorities are to:

  1. Expand service offerings towards higher-value advisory and integrated solutions.

  2. Use technology, including AI, to improve efficiency and competitiveness.

  3. Strengthen workforce capabilities in line with changing customer needs.

  4. Pursue growth through strategic partnerships and initiatives.

The FY2026 results commentary adds that the group needs to transform its business model by adopting AI-driven solutions and moving from traditional services towards higher-value advisory and operational support. Management's message is that FY2026 was a year of "resilience amid transition".

Initiatives in the last 24 months

InitiativeTimingDetail and targetStatusSource
Exit from direct medical servicesFY2025–FY2026Sen Med Holdings struck off (29 May 2025); Express Medical sold (31 March 2026); Medical Services segment discontinuedCompletedAR2026
Office consolidationFY2026–FY2027From 7 to 4 locations in FY2026; target 3 in FY2027In progressAR2026
Digitising tax and compilationFY2026–FY2027Move tax and compilation work to an online platformWork in progress; completion targeted for FY2027AR2026
E-signing for incorporationsFY2027Replace hard-copy signing with electronic signing; store documents on SharePointPlannedAR2026
Integrating subsidiaries' manpowerFY2026–FY2027Integrate Carlin's workflows; consolidate manpower across subsidiariesWork in progressAR2026
Business Manager modelFY2026Every business unit now led by a Business ManagerCompletedAR2026
Malaysia cost baseFY2025–FY2026Hire support staff in MalaysiaOngoingFY2025 results; AR2026
Payment support serviceFY2025New recurring service at MDX Advisory (about S$0.33m revenue uplift)LaunchedFY2025 results
Data Protection TrustmarkFY2027Target certification by 31 March 2027PlannedAR2026
Board gender diversityBy FY2028At least 40% female directorsNot yet met (20%)AR2026
Quoted investment portfolio rotationFY2026Sold Singapore Paincare and Niks Professional holdings (gain S$184k; proceeds S$531k)CompletedFY2026 results

Medium-term targets and guidance

Medinex publishes no financial guidance or medium-term targets. Each results announcement states that no forecast or prospect statement has been disclosed. Its dividend has been 1.68 Singapore cents per share for five consecutive years, but there is no formal dividend policy.

Products & Services

Medinex does not publish a priced product list, version history or flagship brand names beyond its subsidiaries. The catalog below is built from disclosures in AR2026, the FY2023–FY2026 results announcements and AR2020. Pricing models are not publicly disclosed for any offering. Where a service is linked to a subsidiary on the basis of the disclosed activity rather than an explicit statement, it is marked "(inferred)".

Medical Support Services

OfferingDescription and capabilitiesTarget customerEntityYear / status
Turnkey clinic set-upEnd-to-end management of new clinic establishment: premises, fit-out coordination, licensing applications, operational readiness. AR2026 describes it as turnkey solutions plus strategic advice.New GP and specialist practicesMedinex Healthcare Pte. Ltd. (MHC secured additional set-up projects in FY2026)Core since pre-IPO; growth driver in FY2026
Clinic licensing facilitationHelp with applications for relevant clinic licencesNew and relocating clinicsMHC / MCS (inferred)Ongoing
Customised operational support for clinicsValue-added support for primary and secondary care clinics; AR2026 notes a shift towards customised services instead of standard packagesExisting GP and specialist clinicsMHC, NexOngoing
Clinic accounting, tax and secretarial bundleAccounting, tax agent, HR and corporate secretarial services sold to clinicsClinic ownersMCS, MHC (inferred)Ongoing
Related support areas named by managementFY2023 commentary lists clinic set-up support, IT, digital marketing and branding, HR support and financial management supportDoctorsGroupStated focus areas (FY2023)

Business Support Services

OfferingDescription and capabilitiesTarget customerEntityYear / status
Accounting and compilationBookkeeping and compilation of financial statements; migration to an online platform under way (AR2026 target to complete in FY2027)SMEs including F&B, retail, education and beautyMCS, MDX Professional Services, Carlin, MDX Advisory (inferred)Ongoing
Tax agent and tax advisory (income tax and GST)Corporate tax filings and GST advisory led by the Chief Tax Officer, an accredited tax advisorSMEs, clinicsAccTax Management ConsultancyAccTax founded 2006
Corporate secretarialIncorporation, statutory filings, AGM documentation (clients sign AGM documents electronically), directorship-related services; electronic signing plus SharePoint storage targeted for FY2027SMEs, clinicsMCS, MDX Advisory, Carlin (inferred)Ongoing; FY2025 commentary notes heavier compliance and due-diligence burden
HR management and payrollHR consulting and client payroll processing (pass-through client payroll costs raised FY2026 employee expense)SMEs, clinicsArk Leadership & LearningAcquired May 2019
Leadership and organisational development trainingLeadership and organisation development consulting and training; founder is a Gallup-certified strengths coach and an Enterprise Singapore-recognised consultantCorporates across AsiaArk Leadership & LearningFounded 2014
Payment support serviceNew recurring revenue stream added about S$0.33m in FY2025SME clientsMDX AdvisoryLaunched FY2025
Accredited training for the CA (Singapore) designationMedinex is an Accredited Training Organisation for the Chartered Accountant (Singapore) qualificationAccounting traineesMedinex groupOngoing

Pharmaceutical Services

OfferingDescription and capabilitiesTarget customerEntityYear / status
Pharmaceutical and medical product procurementBuys medicines and medical consumables from licensed, authorised Singapore distributors; top three suppliers evaluated regularly; drug labels approved by the Health Sciences Authority; 100% of procurement spend with local suppliersGP and specialist clinicsNex Healthcare Pte. Ltd.Ongoing; a major customer was lost in FY2026 and a major contract is expected to expire in July 2026
Medication delivery to clinicsTwo company-owned vans deliver medication to designated clinics (4,372 litres of petrol consumed in FY2026)ClinicsNex HealthcareOngoing

Medical Services (discontinued 31 March 2026)

OfferingDescriptionTarget customerEntityStatus
Health screening packagesIndividual and corporate health screeningIndividuals, corporatesSen Med group, then Express MedicalDiscontinued
Diagnostic and X-ray servicesImaging and diagnosticsPatients, employersSen Med / Express MedicalDiscontinued
Pre-employment checks and pass/permit medicalsMedical reviews for employment passes, student passes and work permitsEmployers, foreign workers, studentsSen Med / Express MedicalDiscontinued
Vaccination servicesVaccinationsIndividuals, corporatesSen Med / Express MedicalDiscontinued
Customised corporate healthcare plansHealthcare plans tailored to organisationsCorporatesSen Med / Express MedicalDiscontinued
General practice careComprehensive GP-level carePatientsSen Med clinics, including The Family Clinic@Towner (sold in FY2024)Discontinued

Financial Narrative

Definitions used for derived metrics:

Gross profit (derived): revenue − inventories and consumables used − changes in inventories. The company does not report gross profit. This definition matches Moomoo's aggregator figures for FY2022–FY2024.

EBIT (derived): profit before tax + finance costs. It includes other income, fair-value movements, goodwill impairment and share of JV results.

EBITDA (derived): EBIT + depreciation and amortisation, including right-of-use (lease) depreciation under SFRS(I) 16.

Adjusted net profit (derived): reported net profit excluding goodwill and JV impairments, FVTPL fair-value gains and losses, gains and losses on disposal or derecognition of investments and subsidiaries, and liquidation gains. Tax effects are ignored because these items appear largely non-taxable.

Income statement

Sources: FY2023 results (FY2022–FY2023), FY2025 results (FY2024–FY2025), FY2026 results (FY2026). The FY2024 total profit is shown as 867 in the FY2025 income statement and 868 in its statement of changes in equity (rounding).

Adjusted net profit reconciliation (derived):

  • FY2022: 2,896 − 387 FV gain − 471 derecognition gain + 339 goodwill impairment + 90 JV impairment + 34 disposal loss = 2,501

  • FY2023: 1,689 + 816 FV loss = 2,505

  • FY2024: 867 + 1,008 FV loss + 609 subsidiary disposal loss + 84 investment disposal loss = 2,568

  • FY2025: 2,832 − 15 FV gain + 261 impairment − 7 liquidation gain = 3,071

  • FY2026: 2,225 + 1,596 impairment − 586 FV gain − 184 disposal gain − 17 subsidiary disposal gain + 3 write-off = 3,037

Management's own non-GAAP figure, net profit before goodwill impairment, was S$3.09m in FY2025 and S$3.82m in FY2026 (+24%). That figure still includes FY2026's S$0.77m of fair-value and disposal gains on quoted investments.

Per-share data (Singapore cents)

Sources: results announcements. The FY2022 and FY2023 NAV per share figures were calculated on total equity including non-controlling interests; FY2024 onwards uses equity attributable to owners. The bases therefore differ slightly. Weighted average shares were 131,207,540 (FY2022), 132,691,176 (FY2023–FY2025) and 133,254,590 (FY2026).

Dividend composition:

  • FY2022: interim 0.84 + final 0.84

  • FY2023: interim 0.65 + final 1.03

  • FY2024–FY2026: interim 0.84 + final 0.84

Margins and growth (derived)

The four-year revenue CAGR from FY2022 to FY2026 is 0.9% (derived). In practice the group is ex-growth at the top line.

Commentary:

Gross margin: rose from 71% to 80% because revenue shifted away from product-heavy pharmaceutical and medical-services work towards fee-based professional services.

Reported earnings: swung widely, mainly because of non-operating items: fair-value moves on a quoted equity portfolio (S$2.7m at FY2026), goodwill impairments (FY2022, FY2025 and FY2026), and disposal losses in FY2024.

Adjusted net profit: is much steadier, at about S$2.5m in FY2022–FY2024 and about S$3.0–3.1m in FY2025–FY2026. The step-up came from cost discipline (FY2025 employee costs fell S$0.14m despite higher headcount because more staff were hired in Malaysia) and from the exit from loss-making medical services.

FY2026's second half: shows the pressure building. 2H FY2026 net profit was only S$130k against S$1,423k in 2H FY2025, mainly because the Nex impairment fell entirely in that half. 1H FY2026 profit of S$2,095k was boosted by FVTPL gains.

Balance sheet

The single remaining borrowing at 31 March 2026 is "Term loan I": unsecured, fixed-rate, repayable over 60 months, guaranteed by the company, with S$262k left and all of it due within 12 months. In FY2022 there was also a small revolving working-capital line (S$10k).

Commentary: Goodwill is the largest single asset. It was S$6.75m at FY2026, equal to 41% of equity and 35% of total assets. Against that, cash and fixed deposits (S$5.52m) plus quoted investments (S$2.72m) give S$8.25m of liquid assets, equal to about 31% of the current market capitalisation. After the FY2026 impairment, goodwill by cash-generating unit (CGU) is:

Pre-tax discount rates used in impairment testing fell from 14% across all CGUs in FY2025 to between 8.62% and 11.25% in FY2026. Terminal growth assumptions rose to 2.0–3.0% (from 2.6%). Both changes raise value-in-use estimates, so the headroom in the remaining goodwill depends partly on these more favourable assumptions. This is a point for auditors and investors to watch.

Cash flow

Sources: results announcements, statements of cash flows. FY2022 combines S$2,500k of proceeds and S$2,735k of repayments. FY2024 disposal proceeds are S$80k from subsidiaries plus S$1,764k from FVTPL disposals. FY2026 disposal proceeds are S$78k from Express Medical plus S$531k from FVTPL disposals.

Commentary: The business converts earnings to cash reliably. Operating cash flow has stayed between S$2.7m and S$3.4m a year, and maintenance capex is negligible (under 2% of revenue). After lease payments, however, free cash flow of about S$2.1–2.9m only roughly covers the dividend of about S$2.2–2.5m. FY2026 shareholder returns (dividends of S$2.25m plus a S$0.60m buyback) exceeded FCF after leases. The buyback was not a discretionary return: the shares bought back were transferred to the Carlin vendor as deferred consideration. Dividend capacity at the current 1.68-cent rate therefore depends on keeping adjusted profit at about S$2.5m or more.

Ratios (derived)

Method notes:

  • FY2021 opening owners' equity of S$16,657k (FY2023 results, statement of changes in equity) is used for the FY2022 average.

  • ROIC uses a 17% notional tax rate (Singapore's headline corporate tax rate). Invested capital includes quoted investments.

  • Trade payables are not shown separately in the condensed statements, so DPO uses StockAnalysis aggregator figures for accounts payable (S$0.42m, 0.47m, 0.38m, 0.32m, 0.25m).

  • DIO and DPO relate only to the pharmaceutical and medical activities. The cash conversion cycle is therefore an approximation for a services-heavy group.

Commentary: Returns are high for an asset-light services business once FVTPL losses and impairments are stripped out. The balance sheet has de-levered steadily: bank debt fell from S$2.28m to S$0.26m. Receivable days rose to 67 in FY2026 from 57, even though management cites improved collection; trade receivables grew S$0.28m on lower revenue. This is a minor monitorable.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityOwnershipCountryRole (Medinex disclosure, or analyst inference where marked)

Medinex Limited

Listed parent

Singapore

Investment holding

Medinex Corporate Services Pte. Ltd. (MCS)

100%

Singapore

Corporate and business support services (inferred from name and director roles)

Medinex Corporate Services Sdn. Bhd.

100% (via MCS)

Malaysia

Support and back-office team; FY2026 hires were in Malaysia

Medinex Healthcare Pte. Ltd. (MHC)

100%

Singapore

Medical support services; clinic set-up projects (FY2026 results)

MDX Professional Services Pte. Ltd. (formerly Medinex Professional Services)

100%

Singapore

Professional services; separate goodwill CGU

Nex Healthcare Pte. Ltd. (Nex)

100%

Singapore

Pharmaceutical procurement and medical support; headed operationally by COO Lee Kim Hung

AccTax Management Consultancy Private Limited

100%

Singapore

Tax and GST advisory and accounting; founded 2006 by Chai Yee Hoi

Ark Leadership & Learning Pte. Ltd. (Ark LL)

100%

Singapore

HR consulting, leadership training, client payroll; MD is Valerie Low

Carlin Management Services Pte. Ltd.

100%

Singapore

Business support services (acquired 1 April 2022)

MDX Advisory Pte. Ltd. (formerly Medinex Advisory, formerly SKI Corporate Services)

100%

Singapore

Business support services, including a payment support service from FY2025

Healthcare Essentials Pte. Ltd. (HEPL)

—

Singapore

Equity-accounted; share of profit S$141k in FY2026

Sen Med Holdings Pte. Ltd.

Struck off 29 May 2025

Singapore

Former medical services platform

Express Medical Pte. Ltd.

Sold 31 March 2026

Singapore

Former medical services (X-ray and screening)

Segment Overview

SegmentWhat it containsStatus

Medical Support Services

Customised support for GPs and specialists; turnkey clinic set-up and advisory

Continuing

Business Support Services

Accounting, tax, corporate secretarial, HR and payroll, payment support for SMEs across industries

Continuing

Pharmaceutical Services

Procurement of medical and pharmaceutical products for Singapore clinics from authorised distributors

Continuing; major Nex contract expiring July 2026

Medical Services

Health screening, diagnostic and X-ray services, pre-employment and pass/permit medicals, vaccinations, corporate healthcare plans, GP-level care

Discontinued with effect from 31 March 2026

Unallocated

Head-office costs, investment income, share of JV results

Reconciling item

Segment revenue (SGD K)

Segment revenue (SGD K)FY2022FY2023FY2024FY2025FY2026

Medical Support Services

3,7943,9444,5434,4334,545

Business Support Services

2,8453,9884,1804,5924,587

Pharmaceutical Services

3,4053,8433,3083,2882,789

Medical Services

1,9491,172509500493

Unallocated

0184500

Group revenue

11,99312,96512,58512,81312,414

Segment profit before tax (SGD K)

Segment profit before tax (SGD K)FY2022FY2023FY2024FY2025FY2026

Medical Support Services

2,5692,8653,4083,5013,440

Business Support Services

2,3462,6212,5883,0652,966

Pharmaceutical Services

4317-178-170-437

Medical Services

303100-1343126

Unallocated

-1,995-3,561-4,667-3,444-3,574

Group profit before tax

3,2662,0421,0172,9832,421

Segment PBT margin (%) — derived

Segment PBT margin (%) — derivedFY2022FY2023FY2024FY2025FY2026

Medical Support Services

67.772.675.079.075.7

Business Support Services

82.565.761.966.764.7

Pharmaceutical Services

1.30.4-5.4-5.2-15.7

Medical Services

15.58.5-26.36.25.3

Segment revenue YoY growth (%) — derived

Segment revenue YoY growth (%) — derivedFY2023FY2024FY2025FY2026

Medical Support Services

4.015.2-2.42.5

Business Support Services

40.24.89.9-0.1

Pharmaceutical Services

12.9-13.9-0.6-15.2

Medical Services

-39.9-56.6-1.8-1.4

Group

8.1-2.91.8-3.1

Segment share of group revenue (%) — derived (%)

Segment share of group revenue (%) — derived (%)FY2022FY2023FY2024FY2025

Medical Support Services

31.630.436.134.6

Business Support Services

23.730.833.235.8

Pharmaceutical Services

28.429.626.325.7

Medical Services

16.39.04.03.9

Segment assets (SGD K)

Segment assets (SGD K)FY2024FY2025FY2026

Medical Support Services

7611,116593

Business Support Services

2,1252,0842,090

Pharmaceutical Services

2,5142,3231,449

Medical Services

3832790

Unallocated

14,71714,88415,337

Income statement (SGD K)

Income statement (SGD K)FY2022FY2023FY2024FY2025FY2026

Revenue

11,99312,96512,58512,81312,414

Other income

1,6196525383091,083

Inventories and consumables used

3,3483,5672,7252,8652,431

Changes in inventories (expense if positive)

78-841832027

Gross profit (derived)

8,5679,4829,6779,9289,956

Employee benefits expense

4,4905,2685,3465,2025,273

Depreciation and amortisation

650771723553532

Other expenses

1,4602,1473,2951,5462,901

Goodwill impairment (included in other expenses)

339002611,596

Finance costs

8667554641

Share of JV results

-37617468141

EBIT (derived)

3,3522,1101,0713,0292,462

EBITDA (derived)

4,0022,8811,7943,5822,994

Profit before tax

3,2662,0431,0162,9832,421

Income tax

370354149151196

Net profit (total)

2,8961,6898672,8322,225

Net profit attributable to owners

2,8071,6991,0332,8342,224

Adjusted net profit (derived)

2,5012,5052,5683,0713,037

Per-share data (S$ cents)

Per-share data (S$ cents)FY2022FY2023FY2024FY2025FY2026

EPS basic

2.141.280.782.141.67

EPS diluted

2.141.280.782.141.67

Dividend per share (declared for the year)

1.681.681.681.681.68

Payout ratio, % (derived DPS/EPS)

78.5131.3215.478.5100.6

NAV per share

13.3213.4012.1512.6012.28

Margins (%) — derived

Margins (%) — derivedFY2022FY2023FY2024FY2025FY2026

Gross margin

71.473.176.977.580.2

EBIT margin

27.916.38.523.619.8

EBITDA margin

33.422.214.328.024.1

Pre-tax margin

27.215.88.123.319.5

Net margin (total profit)

24.113.06.922.117.9

Adjusted net margin

20.919.320.424.024.5

Effective tax rate

11.317.314.75.18.1

Growth (%) — derived (%)

Growth (%) — derived (%)FY2023FY2024FY2025FY2026

Revenue growth

8.1-2.91.8-3.1

Adjusted net profit growth

0.22.519.6-1.1

Reported attributable profit growth

-39.5-39.2174.4-21.5

Balance Sheet

Balance sheet (SGD K)FY2022FY2023FY2024FY2025FY2026

Total assets

22,98122,59520,50020,68619,469

Cash and bank balances

5,8233,6343,1703,4763,524

Fixed deposits

5165182,0002,0792,000

Cash and fixed deposits

6,3394,1525,1705,5555,524

Financial assets at FVTPL

5,5734,7572,4682,4832,722

Bank borrowings — current

496496506516262

Bank borrowings — non-current

1,7791,2837782620

Total bank borrowings

2,2751,7791,284778262

Lease liabilities (total)

829560801888734

Net cash excl. leases (derived)

4,0642,3733,8864,7775,262

Net cash incl. leases (derived)

3,2351,8133,0853,8894,528

Goodwill

6,5059,2698,6868,4256,747

Total intangible assets

6,6869,5698,8418,5046,747

Investment in joint ventures

208284458464605

Current assets

9,3937,0407,8028,3118,492

Current liabilities

3,2403,1973,0353,2032,429

Working capital (derived)

6,1533,8434,7675,1086,063

Total liabilities

5,5054,8124,3423,9592,950

Equity attributable to owners

17,25317,57016,11816,72016,519

Non-controlling interests

2232134070

Total equity

17,47617,78316,15816,72716,519

Cgu Details

CGUGoodwill at 31 Mar 2026 (SGD K)

Carlin

2,764

MDX Advisory

1,068

MDX/Medinex Professional Services

914

Ark Leadership & Learning

872

Nex Healthcare (after S$1,596k impairment)

794

AccTax

335

Cash flow (SGD K)

Cash flow (SGD K)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

2,8563,0282,6973,3502,708

Capex (PPE + intangibles)

2301933023158

Free cash flow (derived: OCF − capex)

2,6262,8352,6673,3272,550

Lease principal repayments

494483300399419

FCF after lease principal (derived)

2,1322,3522,3672,9282,131

Dividends paid to owners

2,2041,9772,4812,2292,238

Dividends paid to non-controlling interests

13500248

Share buybacks

0000602

Acquisitions (net cash outflow, incl. advances)

3002,334000

Disposal proceeds (subsidiaries + FVTPL)

85601,8440609

Net bank borrowing repayment

235496496506516

Ratios — derived

Ratios — derivedFY2022FY2023FY2024FY2025FY2026

ROE, % (attributable profit / average owners' equity)

16.69.86.117.313.4

ROA, % (net profit / year-end total assets)

12.67.54.213.711.4

ROIC, % (EBIT × 0.83 / [equity + debt + leases − cash])

19.511.06.819.617.0

Current ratio, x

2.902.202.572.593.50

Debt/equity, x (bank borrowings)

0.130.100.080.050.02

Debt incl. leases/equity, x

0.180.130.130.100.06

Net debt/EBITDA, x (negative = net cash)

-1.02-0.82-2.17-1.33-1.76

Interest coverage, x (EBIT / finance costs)

39.031.519.565.860.0

Asset turnover, x (revenue / year-end assets)

0.520.570.610.620.64

DSO, days (net trade receivables / revenue × 365)

61.457.153.057.267.3

DIO, days (inventory / inventories used × 365)

51.659.548.346.249.7

DPO, days (aggregator trade payables / inventories used × 365)

44.749.347.740.537.1

Cash conversion cycle, days

68.367.353.662.979.9

Geographic revenue (SGD K)

Geographic revenue (SGD K)FY2024FY2025FY2026

Group

12,58512,81312,414

Capital Markets

ItemValueSource

Share price

S$0.200

StockAnalysis (aggregator)

52-week range

S$0.190 – S$0.255

StockAnalysis (aggregator)

Other observed prices

S$0.20 (around May 2024, Google Finance); S$0.23 (24 Jul 2026, StockAnalysis)

Aggregators

Shares outstanding

134,543,843

FY2026 results

Market capitalisation

S$26.9m

Derived

Enterprise value (market cap − cash and FD + bank debt + leases)

S$22.4m

Derived

EV also excluding quoted investments

S$19.7m

Derived

Valuation multiple — derived (FY2026 basis)

Value

—

P/E, trailing (attributable profit S$2.224m)

12.1x (StockAnalysis shows 11.98x)

—

P/E on adjusted net profit (S$3.04m)

8.9x—

P/B (NAV 12.28 cents)

1.63x—

EV/EBITDA (S$2.99m)

7.5x—

EV/Sales

1.8x—

Dividend yield (1.68 cents)

8.4%—

Dividend history

Dividend historyFY2022FY2023FY2024FY2025FY2026

DPS declared (S$ cents)

1.681.681.681.681.68

Dividends paid to owners (SGD K)

2,2041,9772,4812,2292,238

Share buybacks (SGD K)

0000602

Debt maturity (SGD K)

Debt maturity (SGD K)Due within 1 yearDue after 1 year

Bank borrowings (Term loan I, unsecured, fixed rate)

2620

Lease liabilities

249485

Analyst Conclusions

Management guidance

Medinex does not give quantitative guidance. Its qualitative outlook (FY2026 results and AR2026) expects the next 12 months to be shaped by:

  • the IP regulatory tightening and its knock-on effect on private specialists;

  • continued consolidation and pricing pressure;

  • AI-driven margin compression in transactional services.

Its response is to move to higher-value advisory, adopt AI and digital tools, and keep integrating its workforce. There are no consensus estimates.

Bull case

  1. Underlying profitability is rising, not falling. Adjusted net profit (derived) went from about S$2.5m in FY2022–FY2024 to about S$3.0–3.1m in FY2025–FY2026, and management's pre-impairment profit grew 24% in FY2026. On adjusted earnings the stock trades at about 9x, or about 6x after deducting liquid assets.

  2. Balance sheet and dividend. Net cash of S$5.3m plus S$2.7m of quoted investments equals about 31% of market capitalisation. Operating cash flow of about S$2.7–3.4m a year supports a dividend yield of about 8.4%.

  3. The weak parts are mostly gone. Medical Services has been exited and Nex goodwill written down to S$0.79m. Office consolidation and a falling headcount (73 to 65) set up margin gains once revenue stabilises.

Bear case

  1. Revenue is shrinking at the edges. Losing the Nex contract in July 2026 could cut further into Pharmaceutical Services revenue (S$2.79m in FY2026). Business Support growth stalled in FY2026 (−0.1%). Group revenue has grown at only 0.9% a year since FY2022.

  2. Structural pressure on the client base. IP tightening and clinic consolidation directly threaten the independent specialists and GPs who drive clinic set-up and compliance revenue. AI-native bookkeeping competitors threaten pricing in Business Support.

  3. Dividend cover is thin, and goodwill is still at risk. FCF after lease payments (S$2.13m in FY2026) was below dividends paid (S$2.25m). The remaining S$6.75m of goodwill relies on FY2026's lower discount rates (8.6–11.3%, down from 14%), so any further shortfall could bring more impairments.

Catalysts and monitorables (next 12 months)

MonitorableTimingWhat to watch
1H FY2027 resultsAround mid-Nov 2026 (expected)Pharmaceutical revenue after the Nex contract expiry; whether the interim dividend stays at 0.84 cents
FY2027 full-year resultsAround May 2027 (expected)Goodwill testing of Carlin and MDX CGUs; adjusted profit relative to the S$2.2m+ dividend outlay
Impact of IP regulationFY2027Demand for MHC clinic set-up projects
Digitisation milestonesBy 31 Mar 2027Completion of the online tax and compilation migration; e-signing; Data Protection Trustmark
Office consolidationFY2027Reduction from 4 to 3 sites
Use of capitalOngoingBolt-on M&A from S$5.3m net cash and S$0.47m of unutilised IPO proceeds; use of the buyback mandate
Investment portfolioOngoingFVTPL valuation swings on S$2.7m of quoted equities

Analyst verdict

Medinex is a small, cash-generative, high-margin professional-services platform. Its reported earnings understate a fairly steady core, but that core is not growing. Over FY2022–FY2026, revenue was flat at about S$12–13m. Meanwhile, the mix shifted decisively towards fee-based Medical Support and Business Support services, which now make up 73.5% of revenue and nearly all segment profit. Underlying profit, after stripping out investment fair-value swings, disposal results and goodwill impairments, has been S$2.5–3.1m a year. The FY2026 headline decline of 21.5% in attributable profit reflects a S$1.60m non-cash goodwill write-down on Nex Healthcare, not a collapse in operations.

The investment question is whether the professional-services core can at least hold its ground as three headwinds converge. First, tighter Integrated Shield Plan rules since April 2026 hit the private specialists Medinex serves. Second, clinic consolidation removes independent doctors from its client pool. Third, AI-led competitors are eroding bookkeeping prices. Management's answer is to move up the value chain, digitise and consolidate offices. That is sensible, but it is also generic and lacks measurable targets.

Valuation already reflects much of this. At about S$0.20 the stock trades at about 12x reported and about 9x adjusted earnings, 1.6x book and about 7.5x EV/EBITDA. It yields about 8.4%, and liquid assets cover about 31% of the market value. The main risk to that yield is that FCF after lease payments roughly equals the dividend. A further revenue decline from the Nex contract expiry and the IP changes could therefore force a cut. The stock is also thinly traded and has no analyst coverage.

Overall assessment: neutral, income-oriented. The case rests on dividend sustainability and cash backing rather than growth. The 1H FY2027 results due in November 2026 are the key test of whether underlying profit can absorb the loss of the Nex contract.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedCommitteesBackground and education

Tan Lee Meng

Non-Executive Chairman (described as non-independent in the 2026 AGM results)

22 May 2017; re-elected 24 Jul 2026

Member of AC, NC and RC

Investor and incubator. Set up LinksTech Holding (2000). Former director of Asia Progress International. Former independent director of BRC Asia and Hisaka Holdings (now Regal International); former non-executive director of See Hup Seng (now SHS Holdings). BSc summa cum laude, Oklahoma City University (1993); MBA (Investment and Finance), University of Hull

Jessie Low Mui Choo

Executive Director and CEO

1 Jun 2017; re-elected 24 Jul 2026

Attends AC, NC and RC meetings by invitation

Audit assistant at Ernst & Young (1990). Head of internal audit at Pan Malayan Holdings (1995). Founded El-Shaddai Consultants (1996) and JK Corporate Services (2003). Registered Ark Assurance (2005). Principal partner at Ark Alliance LLP (2014–2017). Lead Independent Director of Medtecs International. MBA, University of Adelaide; Registered Public Accountant; FCA (ISCA); ACCA member; Accredited Tax Practitioner

Lim Tai Toon

Lead Independent Non-Executive Director

14 Nov 2018; re-elected 25 Jul 2025

Chairs AC; member of NC and RC

14 years in the Singapore Armed Forces (including Army Budget Controller). Head of Corporate Affairs at Ipco International. Chairman and MD of Startech Electronics. Executive Director of Eastgate Technology. Chairman of Ark Lanka Holdings and Food Studio. Former Lead Independent Director of Medtecs (2010–2024). B.Acc, NUS (1985); MBA, Brunel; Master of Business IT, Curtin

Ye Binlin

Independent Non-Executive Director

1 Sep 2020; re-elected 25 Jul 2025

Chairs RC; member of NC and AC

CFO and chief accountant for COSCO group companies (2001–2014). Executive Director and CFO of AnAn International (2017–2018). Independent director of Emerging Towns & Cities Singapore. BEcon, Shanghai Maritime University; Senior Accredited Director, Singapore Institute of Directors

Venkata Subramanian s/o Sreenivasan

Independent Non-Executive Director

23 Aug 2021; re-elected 25 Jul 2024

Chairs NC; member of RC and AC

Economist at the National Productivity Board (1987). Senior correspondent and news editor at The Business Times (1993–2017). Executive Editor, SPH Radio (2017–2021). Associate Editor, The Straits Times (2021–). BA (Economics and Political Science), Brandon University; MA (Economics), University of Manitoba

Executive Leadership Team

NameTitleBackground

Jessie Low Mui Choo

CEO

See board table

Lee Kim Hung

Chief Operating Officer; heads Nex Healthcare operations

SAF (1993–2010). ST Kinetics (2010–2011). CEO of the Singapore Badminton Association (2011–2013). COO, then CEO, of Northeast Health International (from 2013). MBA, NTU; MSc, University of Central Florida; BEng (First Class, Aeronautical), University of London

Low Siam Kiang

Financial Controller

Joined 2010. Chief Integration Officer from June 2022; re-appointed FC on 16 January 2024. Director of most subsidiaries. Accredited Tax Practitioner; CA (ISCA)

Valerie Low (Low Mui Keow), age 54

Chief Business Development Officer; MD of Ark LL; ESG Lead Facilitator

Former Vice President at UOB; former regional talent lead at FedEx. Founded Ark LL in 2014. MA, George Washington University; BA, NUS. Sister of the CEO

Chai Yee Hoi

Chief Tax Officer; director of AccTax

Inland Revenue Department (1986). IRAS tax audit (from 1993). GST Manager at Ernst & Young (2000). GST Consultant at Robin Chia & Co. (2005). Founded AccTax in 2006. Accredited Tax Advisor; FCCA

Directors' Remuneration

ItemDetailSource

Directors' fees approved for FY2027

S$106,250 in aggregate, payable quarterly in arrears

Results of AGM, 24 July 2026

CEO and key management remuneration (salary, bonus, stock, total)

Catalist companies typically disclose remuneration in bands.

—

Share plans

Medinex Performance Share Plan and Medinex Employee Share Option Scheme; issuance mandates renewed at the 2026 AGM. No options outstanding at 31 March 2026.

AGM results; FY2026 results Note 17

Major Shareholders

HolderStakeSource

Other substantial shareholders, top 20 holders, free float

AR2026 "Statistics of Shareholding" (p.

—

Institutional ownership (top 10)

Not publicly disclosed; no institutional holders identified

—

Treasury shares

Nil at 31 March 2026

FY2026 results Note 17

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypePositioning relative to Medinex

Business Support

Boardroom (Singapore)

Private; formerly SGX-listed

Larger, regional corporate secretarial and share registry provider

Business Support

Tricor (Singapore)

Private, regional

Larger, regional corporate services and payroll provider

Business Support

Sleek

Private, digital

Low-cost online incorporation and accounting; part of the pricing pressure management cites

Business Support

Osome

Private, digital

AI and app-led bookkeeping; part of the AI disruption threat

Business Support

In.Corp / Acclime

Private, regional

Corporate services for SMEs and foreign investors

Business Support

Small local accounting and secretarial firms

Fragmented

FY2025 commentary notes many smaller low-cost players

Medical Support

Clinic-consultancy firms and in-house practice managers of larger groups

Fragmented / private

Consolidation of clinics into larger groups internalises these services

Medical Support / clinics

Fullerton Health, Healthway Medical, Raffles Medical Group (SGX-listed)

Large healthcare groups

Acquirers of independent practices, which shrinks Medinex's addressable market of standalone clinics

Pharmaceutical

Zuellig Pharma, DKSH (healthcare), local wholesalers

Large distributors

Medinex procures from authorised distributors such as these and resells; it has little scale advantage

Medical Services (exited)

Fullerton Health, Raffles Medical, specialist screening and pre-employment centres

Large providers

Explains why Medinex exited the segment

Competitor Detail

Metric (latest fiscal year)Medinex FY2026

Revenue

S$12.4m

Revenue growth

-3.1%

Net margin

17.9% (adjusted 24.5%)

R&D intensity

0%

Recent Developments

As a Catalist micro-cap, Medinex issues few material announcements.

Company Snapshot

$9.5M

Revenue

65

Employees

2009

Founded

Singapore

Headquarters

SWOT Analysis

Strengths

  • High-margin core. Medical Support and Business Support segments earned PBT margins of 75.7% and 64.7% in FY2026, before head-office costs (FY2026 results, Note 4).
  • Strong cash generation. Operating cash flow was between S$2.70m and S$3.35m in each of the last five years, with capex under S$0.25m a year (results announcements).
  • Net cash and liquid investments. Cash and fixed deposits of S$5.52m plus S$2.72m of quoted investments, against S$0.26m of bank debt, at 31 March 2026.
  • Consistent dividend. 1.68 cents per share declared every year from FY2022 to FY2026, a yield of about 8.4% at S$0.20.
  • Stable underlying earnings. Adjusted net profit (derived) was S$2.50–3.07m every year from FY2022 to FY2026, despite large reported swings.
  • Gross margin expansion. Derived gross margin rose from 71.4% (FY2022) to 80.2% (FY2026) as the mix shifted to fee-based services.

Weaknesses

  • Top line not growing. Revenue CAGR from FY2022 to FY2026 was 0.9%, and revenue fell 3.1% in FY2026.
  • Goodwill-heavy balance sheet. Goodwill of S$6.75m equals 41% of equity. There were impairments in FY2022 (S$339k), FY2025 (S$261k) and FY2026 (S$1,596k).
  • Loss-making pharmaceutical segment. PBT was −S$437k in FY2026 (−S$170k in FY2025), and the segment depends on a few large customers at Nex.
  • Earnings volatility from the investment portfolio. FVTPL swings ranged from a S$1,008k loss (FY2024) to a S$586k gain (FY2026).
  • High head-office cost. Unallocated expenses were S$3.57m in FY2026, about 29% of revenue.
  • Family concentration in management. The CEO's spouse and sister hold managerial roles (Rule 704(10) disclosures), and the CEO is a substantial shareholder.

Opportunities

  • Advisory upsell. Management plans to move towards higher-value advisory and integrated solutions (AR2026).
  • AI and digital efficiency. Online tax and compilation and e-signing targeted for FY2027 could lift margins on a headcount that is already falling (73 to 65).
  • Clinic set-up demand. MHC secured additional projects in FY2026, and Medical Support revenue grew 2.5%.
  • Bolt-on M&A. About S$0.47m of IPO proceeds remain for acquisitions, plus net cash of S$5.3m (FY2026 results).
  • Recurring payment-support revenue. Introduced at MDX Advisory in FY2025, worth about S$0.33m.
  • Further cost savings. Office reduction from 4 to 3 sites, and continued Malaysia hiring (AR2026).

Threats

  • IP regulation from 1 April 2026 may slow private specialist practice growth (FY2026 commentary).
  • Nex contract expiry in July 2026 removes more pharmaceutical revenue in FY2027 (FY2026 results).
  • Healthcare consolidation is shrinking the pool of independent clinics (FY2026 commentary).
  • AI-native, low-cost competitors are compressing bookkeeping margins (FY2026 commentary).
  • Wage inflation in finance and compliance talent (FY2025 commentary).
  • Rising compliance burden for corporate secretarial and directorship services (FY2025 commentary).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr–Sep 2025 (1H FY2026)Bought back 814,000 shares, held in treasury FY2026 results Note 17Used to settle the Carlin deferred consideration
FY2026 (date not specified)Issued 1,852,667 new shares and transferred 814,000 treasury shares to Ms. Lee Lay Lian (Carlin vendor) FY2026 results Note 17Carlin deferred consideration fully settled; about 1.4% dilution
29 May 2025Sen Med Holdings Pte. Ltd. struck off AR2026Legal exit from former medical-services platform
30 May 2025FY2025 results: revenue S$12.81m (+1.8%), PBT S$2.98m (+194%), final DPS 0.84 cents proposed FY2025 results announcementEarnings recovery after FY2024 investment losses
25 Jul 2025AGM: Lim Tai Toon and Ye Binlin re-elected AR2026Board continuity
FY2026 (date not specified)Sold quoted holdings in Singapore Paincare and Niks Professional (gain S$184k) FY2026 resultsInvestment portfolio rotation
FY2026Loss of a major customer at Nex Healthcare FY2026 resultsPharmaceutical revenue −15%
FY2026Additional clinic set-up projects secured by MHC FY2026 resultsMedical Support revenue +2.5%
FY2026Offices consolidated from 7 to 4; new office renovated AR2026Cost and emissions reduction
FY202611 departures and 3 hires; headcount down to 65 AR2026Manpower consolidation and technology adoption
12 Nov 20251H FY2026 results: revenue S$6.05m, net profit S$2.10m; interim DPS 0.84 cents SGX announcement; FY2026 resultsStrong first half, helped by fair-value gains
17–18 Dec 2025Interim dividend ex-date and record date SGX corporate action notice—
30 Dec 2025Interim dividend of S$0.0084 per share paid SGX corporate action noticeDividend continuity
31 Mar 2026Express Medical Pte. Ltd. sold; Medical Services segment discontinued AR2026Portfolio simplification
1 Apr 2026Tighter Integrated Shield Plan (IP) rules take effect FY2026 results commentaryManagement expects pressure on private specialists and day-surgery centres, which are its client base
19 May 2026FY2026 results: revenue S$12.41m (−3.1%); attributable profit S$2.22m (−21.5%); S$1.60m Nex goodwill impairment; final DPS 0.84 cents proposed FY2026 results announcementHeadline earnings decline; underlying profit up
19 May 2026Disclosure that a major Nex contract is expected to expire in July 2026 FY2026 resultsFurther pharmaceutical revenue risk in FY2027
~9 Jul 2026Annual Report 2026 ("Driving Momentum, Delivering Value") published AR2026Includes the sustainability report and FY2027 ESG targets
9 Jul 2026Final dividend book-closure notice: ex-date 19 Aug, record 20 Aug, payment 4 Sep 2026 SGX corporate action notice—
Jul 2026Expected expiry of the major Nex contract FY2026 resultsRevenue headwind materialises in FY2027
24 Jul 2026AGM: all nine resolutions passed with 100% for; Tan Lee Meng and Jessie Low re-elected; Forvis Mazars re-appointed; S$106,250 directors' fees approved; share-plan and buyback mandates renewed Results of AGMGovernance continuity
4 Sep 2026Final dividend paid (S$0.0084 per share, about S$1.13m) SGX corporate action noticeFY2026 total DPS 1.68 cents
5 Oct 2026Shares close at S$0.200; 52-week range S$0.19–0.255 StockAnalysis (aggregator)Market capitalisation about S$26.9m
Expected around mid-Nov 20261H FY2027 results, based on prior filing pattern (12 Nov 2025; 14 Nov 2024; 14 Nov 2022) Analyst expectationFirst reading of the Nex contract loss and IP regulation impact

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue rose from SGD 12 Mn in FY2022 to SGD 12.4 Mn in FY2026.
Medinex Limited — Income Statement: Revenue & Gross Profit
Series (SGD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue121312.612.812.4
Gross profit8.69.59.79.910

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. [FY2026 Full Year Results announcement (19 May 2026)]( (links.sgx.com)
  2. [Annual Report 2026]( (links.sgx.com)
  3. [FY2025 Full Year Results announcement (30 May 2025)]( (links.sgx.com)
  4. [FY2023 Full Year Results announcement (30 May 2023)]( (links.sgx.com)
  5. [Annual Report 2020]( (links.sgx.com)
  6. [Annual Report 2018]( (links.sgx.com)
  7. [FY2018 Results announcement]( (links.sgx.com)
  8. [FY2020 Full Year Results announcement]( (links.sgx.com)
  9. [Results of AGM, 24 July 2026]( (links.sgx.com)
  10. [Results of AGM, 25 July 2025]( (links.sgx.com)
  11. [Final dividend notice FY2026 (9 July 2026)]( (links.sgx.com)
  12. [Interim dividend corporate action FY2026]( (links.sgx.com)
  13. [1H FY2026 Half Yearly Results notice (12 November 2025)]( (links.sgx.com)
  14. [StockAnalysis — Medinex quote]( (stockanalysis.com)
  15. [StockAnalysis — income statement]( (stockanalysis.com)
  16. [StockAnalysis — balance sheet]( (stockanalysis.com)
  17. [Google Finance — OTX:SGX]( (google.com)
  18. [TipRanks — revenue history]( (tipranks.com)
  19. [Morningstar — company profile]( (dfd.dr.morningstar.com.au)
  20. [Moomoo — income statement]( (moomooapp.com)
  21. [Minichart — FY2026 results analysis]( (minichart.com.sg)
  22. [Seeking Alpha — MDNXF balance sheet]( (seekingalpha.com)
  23. FY2026 revenue decline is 3.11% in the results announcement and 3.12% in AR2026.
  24. FY2026 other income growth is 250.49% in the results announcement and 250.84% in AR2026.
  25. The FY2026 increase in investment in joint ventures is stated as S$0.01m in the results commentary, but the balance sheet and AR2026 show S$0.14m. The balance sheet figure is used.
  26. FY2024 total profit is 867 in the income statement and 868 in the statement of changes in equity.
  27. TipRanks labels fiscal years as ending December; Medinex's fiscal year ends in March.
  28. Employee counts differ across aggregators (Google Finance 80, TipRanks 73, Morningstar 71) and the filing (65 at 31 March 2026). The filing is used.

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.